Arranging Arrakis' syndicate
How Arrakis is plotting a path forward with its RNA-targeting small molecules
As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become an integrated, publicly traded biopharma.
Arrakis Therapeutics Inc. has begun its first four programs developing RNA-targeting small molecules -- "rSMs" -- including three oncology programs and one cardiovascular project. But